Logo image of KMTS

KESTRA MEDICAL TECHNOLOGIES (KMTS) Stock Fundamental Analysis

NASDAQ:KMTS - Nasdaq - BMG524411052 - Common Stock - Currency: USD

22.57  -1.18 (-4.97%)

Premarket: 22.5 -0.07 (-0.31%)

Fundamental Rating

1

Taking everything into account, KMTS scores 1 out of 10 in our fundamental rating. KMTS was compared to 189 industry peers in the Health Care Equipment & Supplies industry. KMTS has a bad profitability rating. Also its financial health evaluation is rather negative. KMTS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KMTS has reported negative net income.
In the past year KMTS has reported a negative cash flow from operations.
KMTS Yearly Net Income VS EBIT VS OCF VS FCFKMTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -83.03%, KMTS is not doing good in the industry: 78.31% of the companies in the same industry are doing better.
The Return On Equity of KMTS (-365.94%) is worse than 83.60% of its industry peers.
Industry RankSector Rank
ROA -83.03%
ROE -365.94%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KMTS Yearly ROA, ROE, ROICKMTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2023 2024 0 -1K -2K -3K

1.3 Margins

The Gross Margin of KMTS (1.30%) is worse than 82.54% of its industry peers.
KMTS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KMTS Yearly Profit, Operating, Gross MarginsKMTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

KMTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
KMTS has about the same amout of shares outstanding than it did 1 year ago.
The debt/assets ratio for KMTS has been reduced compared to a year ago.
KMTS Yearly Shares OutstandingKMTS Yearly Shares OutstandingYearly Shares Outstanding 2021 2023 2024 10M 20M 30M 40M
KMTS Yearly Total Debt VS Total AssetsKMTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of 0.73, we must say that KMTS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.73, KMTS perfoms like the industry average, outperforming 48.15% of the companies in the same industry.
A Debt/Equity ratio of 1.57 is on the high side and indicates that KMTS has dependencies on debt financing.
KMTS has a worse Debt to Equity ratio (1.57) than 80.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.57
Debt/FCF N/A
Altman-Z 0.73
ROIC/WACCN/A
WACC8.91%
KMTS Yearly LT Debt VS Equity VS FCFKMTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2023 2024 0 20M -20M 40M -40M -60M -80M

2.3 Liquidity

A Current Ratio of 2.81 indicates that KMTS has no problem at all paying its short term obligations.
The Current ratio of KMTS (2.81) is comparable to the rest of the industry.
KMTS has a Quick Ratio of 2.81. This indicates that KMTS is financially healthy and has no problem in meeting its short term obligations.
KMTS's Quick ratio of 2.81 is fine compared to the rest of the industry. KMTS outperforms 62.43% of its industry peers.
Industry RankSector Rank
Current Ratio 2.81
Quick Ratio 2.81
KMTS Yearly Current Assets VS Current LiabilitesKMTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

KMTS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.26%.
Looking at the last year, KMTS shows a very strong growth in Revenue. The Revenue has grown by 264.53%.
EPS 1Y (TTM)-16.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)264.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KMTS Yearly Revenue VS EstimatesKMTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 5M 10M 15M 20M 25M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KMTS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KMTS Price Earnings VS Forward Price EarningsKMTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KMTS Per share dataKMTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KMTS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KESTRA MEDICAL TECHNOLOGIES

NASDAQ:KMTS (5/5/2025, 8:22:35 PM)

Premarket: 22.5 -0.07 (-0.31%)

22.57

-1.18 (-4.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-14 2025-04-14/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change0%
Market Cap1.16B
Analysts85
Price TargetN/A
Short Float %3.93%
Short Ratio4.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 41.67
P/FCF N/A
P/OCF N/A
P/B 42.06
P/tB 42.06
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0.54
BVpS0.54
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -83.03%
ROE -365.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.3%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 1.57
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 184.47%
Cap/Sales 73.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.81
Quick Ratio 2.81
Altman-Z 0.73
F-ScoreN/A
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)264.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.72%
OCF growth 3YN/A
OCF growth 5YN/A